Cure8 research brief
The review directly compares randomized-trial evidence for JAK inhibitors in moderate-to-severe Crohn's disease and highlights which regimens (notably upadacitinib) showed the most consistent efficacy signals, information that could inform treatment decisions and future research.
Clinicians treating moderate-to-severe Crohn's disease; researchers focused on IBD therapeutics and comparative-effectiveness studies; patients considering JAK-inhibitor therapy or following emerging IBD drug evidence.
The paper reviewed 12 RCTs (5,129 patients) testing JAK inhibitors, primarily upadacitinib (multiple doses) and filgotinib. Upadacitinib 45 mg once daily showed a statistically significant effect for clinical remission versus placebo; other upadacitinib dosing regimens ranked highest for endoscopic outcomes in the network.
The authors note wide credible intervals and limited direct comparisons, so rankings are exploratory rather than definitive. The analysis did not find clear safety differences across regimens in the available trials, but the authors emphasize imprecision due to a sparse evidence network.
This means clinicians and patients should interpret comparative rankings cautiously and consider individual clinical context and trial details when making treatment decisions.
Network meta-analysis findings are exploratory when head-to-head trials are lacking; the authors report wide credible intervals and a sparse evidence network which limits clinical applicability of ranking results.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...
This study examines a combination of ustekinumab plus low‑dose upadacitinib for patients with refractory Crohn’s disease — a group with limited options after failing anti‑TNF and single‑agent therapy. Results could...
The study identifies a cellular mechanism (JAK1-STAT6 pathway) by which upadacitinib can lower IL13RA2 — a molecule tied to inflammation and anti-TNF resistance — which could help explain how JAK inhibitors work in IBD...
